BR112017026189A2 - tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4 - Google Patents
tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4Info
- Publication number
- BR112017026189A2 BR112017026189A2 BR112017026189A BR112017026189A BR112017026189A2 BR 112017026189 A2 BR112017026189 A2 BR 112017026189A2 BR 112017026189 A BR112017026189 A BR 112017026189A BR 112017026189 A BR112017026189 A BR 112017026189A BR 112017026189 A2 BR112017026189 A2 BR 112017026189A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- specifically binds
- binding portion
- cxcr4
- cancer treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
esta descrição refere-se a um método para tratar um indivíduo aflito com um câncer compreendendo administrar ao indivíduo uma combinação de quantidades terapeuticamente efetivas de um anticorpo ou uma porção de ligação de antígeno do mesmo que especificamente liga-se à morte programada-1 (pd-1) ou ao ligante de morte programada-1 (pd-l1), e um anticorpo ou uma porção de ligação de antígeno do mesmo que especificamente liga ao receptor 4 da quimiocina c-x-c (cxcr4) ou à quimiocina 12 de motivo c-x-c (cxcl12). a descrição também fornece um kit para tratar um indivíduo aflito com um câncer, o kit compreendendo uma ou mais dosagens de um anticorpo ou uma porção de ligação de antígeno do mesmo que especificamente liga a pd-1 ou a pd-l1, uma ou mais dosagens de um anticorpo ou uma porção de ligação de antígeno do mesmo que especificamente liga a cxcr4 ou a cxcl12, e instruções para uso dos anticorpos ou porções dos mesmos para tratar o indivíduo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562174931P | 2015-06-12 | 2015-06-12 | |
PCT/US2016/037207 WO2016201425A1 (en) | 2015-06-12 | 2016-06-13 | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017026189A2 true BR112017026189A2 (pt) | 2018-08-14 |
Family
ID=56194616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017026189A BR112017026189A2 (pt) | 2015-06-12 | 2016-06-13 | tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20180179282A1 (pt) |
EP (1) | EP3307778A1 (pt) |
JP (1) | JP2018516969A (pt) |
CN (1) | CN108026173A (pt) |
BR (1) | BR112017026189A2 (pt) |
CA (1) | CA2989144A1 (pt) |
EA (1) | EA201792522A1 (pt) |
MX (1) | MX2017015811A (pt) |
WO (1) | WO2016201425A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105330741B (zh) * | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
EA037351B8 (ru) * | 2012-05-15 | 2021-04-29 | Бристол-Майерс Сквибб Компани | Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4 |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
US11357742B2 (en) | 2015-12-14 | 2022-06-14 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
EP3389634B1 (en) | 2015-12-14 | 2021-10-06 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
CN108883091A (zh) | 2015-12-22 | 2018-11-23 | X4 制药有限公司 | 用于治疗免疫缺陷病的方法 |
WO2017127811A1 (en) * | 2016-01-22 | 2017-07-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
CA3027495A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
JP6994767B2 (ja) | 2016-06-21 | 2022-01-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
EP3808748A1 (en) | 2016-06-21 | 2021-04-21 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
US20190307821A1 (en) * | 2016-11-29 | 2019-10-10 | Health Research, Inc. | Methods and compositions for cancer therapy |
MX2019011324A (es) | 2017-03-23 | 2020-01-21 | Massachusetts Gen Hospital | Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano. |
US20190233524A1 (en) * | 2017-09-18 | 2019-08-01 | Tcm Biotech International Corp. | Therapeutic combination and method for treating cancer |
CN109517039B (zh) * | 2017-09-20 | 2021-03-19 | 尚华医药科技(江西)有限公司 | 一种肽类化合物、其应用及含其的组合物 |
CN111465613A (zh) * | 2017-11-07 | 2020-07-28 | X4 制药有限公司 | 癌症生物标志物及其使用方法 |
EP3765519B1 (en) * | 2018-03-13 | 2024-01-17 | Fundación para la Investigación Biomédica del Hospital Universitario la Paz | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
CN113164600A (zh) * | 2018-10-17 | 2021-07-23 | 百欧林纳克斯有限公司 | 转移性胰脏腺癌的治疗 |
WO2020135415A1 (zh) * | 2018-12-24 | 2020-07-02 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
EP3941463A1 (en) * | 2019-03-22 | 2022-01-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
TW202408562A (zh) | 2022-04-13 | 2024-03-01 | 美商建南德克公司 | 治療性蛋白質之醫藥組成物及使用方法 |
WO2023201291A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
WO2023215799A1 (en) * | 2022-05-04 | 2023-11-09 | Janux Therapeutics, Inc. | Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
CN115487146B (zh) * | 2022-10-28 | 2023-07-18 | 宁夏医科大学 | 一种阻断cxcr4/pd-l1双信号的三药共递送纳米体系及其制备方法和应用 |
WO2024120084A1 (zh) * | 2022-12-07 | 2024-06-13 | 宜明昂科生物医药技术(上海)股份有限公司 | 使用cd24抗体和pd-1-pd-l1通路阻断抗体的癌症联合疗法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
PT2439273T (pt) | 2005-05-09 | 2019-05-13 | Ono Pharmaceutical Co | Anticorpos monoclonais humanos para morte programada 1 (pd- 1) e métodos para o tratamento de cancro utilizando anticorpos anti-pd-1 isoladamente ou em combinação com outros imunoterapêuticos |
CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
EP2046834B9 (en) | 2006-08-11 | 2013-04-10 | Ono Pharmaceutical Co., Ltd. | Monoclonal antibodies against stromal derived factor-1 (sdf-1) |
JP5417175B2 (ja) | 2006-10-02 | 2014-02-12 | メダレックス・リミテッド・ライアビリティ・カンパニー | Cxcr4に結合するヒト抗体およびその使用 |
FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
KR20100133012A (ko) | 2008-05-14 | 2010-12-20 | 일라이 릴리 앤드 캄파니 | 항-cxcr4 항체 |
US7892546B2 (en) | 2008-05-14 | 2011-02-22 | Eli Lilly And Company | Anti-CXCR4 antibodies |
CN104740610A (zh) * | 2008-08-25 | 2015-07-01 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
EP2172485A1 (en) | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
RU2571204C3 (ru) | 2009-11-24 | 2020-12-14 | Медиммьюн Лимитед | Специфические связывающие агенты против в7-н1 |
JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン,エルエルシー | B7−h1およびpd−1に結合する抗体およびその他の分子 |
EP2734234A4 (en) | 2011-07-20 | 2015-01-28 | Medimmune Ltd | ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF |
HUE043001T2 (hu) | 2011-11-09 | 2019-07-29 | Bristol Myers Squibb Co | Hematológiai malignómák kezelése anti-CXCR4 antitesttel |
EA036814B9 (ru) | 2011-11-28 | 2021-12-27 | Мерк Патент Гмбх | Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение |
EA037351B8 (ru) | 2012-05-15 | 2021-04-29 | Бристол-Майерс Сквибб Компани | Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4 |
KR102410078B1 (ko) | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
PL2925350T3 (pl) | 2012-12-03 | 2019-07-31 | Bristol-Myers Squibb Company | Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc |
CN113683695A (zh) | 2013-08-02 | 2021-11-23 | 辉瑞公司 | 抗cxcr4抗体及抗体-药物缀合物 |
JP2016527303A (ja) | 2013-08-05 | 2016-09-08 | ケンブリッジ エンタープライズ リミテッド | がん免疫療法におけるcxcr4シグナル伝達の阻害 |
-
2016
- 2016-06-13 CA CA2989144A patent/CA2989144A1/en not_active Abandoned
- 2016-06-13 CN CN201680047043.2A patent/CN108026173A/zh active Pending
- 2016-06-13 WO PCT/US2016/037207 patent/WO2016201425A1/en active Application Filing
- 2016-06-13 US US15/735,055 patent/US20180179282A1/en not_active Abandoned
- 2016-06-13 MX MX2017015811A patent/MX2017015811A/es unknown
- 2016-06-13 EA EA201792522A patent/EA201792522A1/ru unknown
- 2016-06-13 EP EP16731754.4A patent/EP3307778A1/en not_active Withdrawn
- 2016-06-13 BR BR112017026189A patent/BR112017026189A2/pt not_active IP Right Cessation
- 2016-06-13 JP JP2017564421A patent/JP2018516969A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2989144A1 (en) | 2016-12-15 |
WO2016201425A9 (en) | 2017-01-19 |
US20180179282A1 (en) | 2018-06-28 |
EA201792522A1 (ru) | 2018-05-31 |
WO2016201425A1 (en) | 2016-12-15 |
CN108026173A (zh) | 2018-05-11 |
JP2018516969A (ja) | 2018-06-28 |
MX2017015811A (es) | 2018-04-10 |
EP3307778A1 (en) | 2018-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017026189A2 (pt) | tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4 | |
CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
BR112018011781A2 (pt) | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica | |
BR112019023754A2 (pt) | anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica. | |
BR112017010324A2 (pt) | método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula | |
MX2019001503A (es) | Tratamiento conjunto contra el cancer. | |
BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
BR112018075198A2 (pt) | método para o tratamento de câncer ou uma doença associada a patógeno, composição farmacêutica, e kit | |
CL2021003196A1 (es) | Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850) | |
EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
CR20170600A (es) | Anticuerpos del factor x1 y métodos de uso | |
BR112016016207A2 (pt) | Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos | |
BR112016016699A2 (pt) | Anticorpos humanos para pd-1 | |
BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
BR112019010595A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto. | |
BR112021019334A2 (pt) | Anticorpos de cadeia pesada que se ligam ao psma | |
CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
BR112019023909A8 (pt) | Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab | |
CO2020013833A2 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
CO2021008665A2 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
BR112018008900A8 (pt) | composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas | |
BR112022001395A2 (pt) | Métodos para administrar anticorpos anti-siglec-8 e corticosteroides | |
BR112019011350A2 (pt) | terapia de combinação | |
BR112021017810A2 (pt) | Anticorpos tsg-6 e usos dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2623 DE 13/04/2021. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |